First-in-class liver MRI contrast agent, which addresses a very specific unmet medical need for which there are no good alternatives available today. Treatment of liver cancer and liver metastases is an important challenge within oncology. Adequate visualization of liver tumors and metastases is critical for making the right treatment decisions. Contrast-enhanced MRI is the gold standard procedure for examining patients with suspected or known tumors or metastases. The most used contrast agents are all based on the heavy metal gadolinium. In patients with severe kidney impairment, use of gadolinium-based contrast agents has been associated with an increased risk of a very severe side effect called Nephrogenic Systemic Fibrosis (NSF), which may even have a lethal outcome. Both the European and US regulatory authorities have, for that reason, issued warnings for the use of gadolinium-based contrast agents in this group of patients. The consequence is that patients with impaired kidney function typically will get an MRI without contrast, resulting in liver images of suboptimal quality, with the risk that their cancer is not managed in the best possible way. We envision that Orviglance, which is based on manganese, will address this unmet medical need and in the future become an efficacious non-gadolinium contrast agent for liver MRI in patients with impaired kidney function. In May, we shared the positive results from the SPARKLE Phase 3 study. We found that Orviglance-enhanced liver MRIs were superior to unenhanced MRIs. All three readers of the images reported strong, statistically significant results. We also noted that the common side effects were related to the gastrointestinal tract, which aligns with findings from previous studies on Orviglance. We have now finished the full study report for SPARKLE, and I'd like to share some of the key data and conclusions. First, let's have a look at the primary endpoint. The enhancement of focal liver lesion visualization was assessed through two co-primary variables: border delineation and lesion contrast. These were rated on a scale of 1 to 4 by three independent readers, and the mean scores for each patient, aggregated across all readers, are displayed in these bar charts. In the upper panel are the border delineation, and in the lower panel, you can see the lesion contrast. The height of each bar indicates the percentage of all patients receiving that score. Blue bars represent unenhanced images. Imaging results. While orange bars show the combined evaluation of unenhanced and Orviglance-enhanced images, scores for unenhanced images predominantly range from 2.1 to 3. In contrast to the previous assessment, the combined evaluation revealed a shift towards scores of 3 to 4, clearly indicating improved lesion visualization with Orviglance.
The statistical evaluation compared Orviglance-enhanced scores with unenhanced scores within patients, and the mean paired differences, along with their 95% confidence intervals, are presented here. Notably, all mean paired differences are positive, indicating that Orviglance MRI is superior to unenhanced images for visualizing focal liver lesions. The analysis yielded a p-value of less than 0.001 for both variables across all readers, underscoring the significant advantage of combined MRI. To further validate our findings, subgroup analyses were conducted, and in every subgroup combined MRI was preferred over unenhanced MRI. The study also included various secondary efficacy analyses and safety evaluations. The secondary endpoints aim to assess different aspects of Orviglance's performance, reinforcing the primary conclusion that Orviglance enhances lesion visualization. Lesion visualization. Among the secondary endpoints, we observed that Orviglance increased the detection of lesions, measured as the proportion of patients with at least one additional lesion identified compared to unenhanced. Additionally, Orviglance improved the ability to detect and measure smaller lesions, with the smallest lesion being on average two millimetres smaller with Orviglance compared to unenhanced imaging. The results from other secondary endpoints consistently demonstrate the superiority of Orviglance over unenhanced MRI, with no analysis favoring unenhanced MRI. These endpoints include a quantitative assessment of signal intensity in the images, recommendations for the next step in treatment, and reader confidence in detecting and localizing lesions. Importantly, the performance of Orviglance alone was similar to when both Orviglance-enhanced and Unenhanced images were evaluated together. The primary safety analysis indicated that no serious adverse drug reactions were observed, and more than 80% of reported reactions were mild and short-lived, primarily related to the gastrointestinal tract, including nausea, diarrhea, and vomiting. The safety results from this vulnerable patient population were consistent with previous studies. With SPARKLE, we have completed the clinical development. The comprehensive clinical program includes a total of 286 patients and healthy volunteers in nine clinical studies. Taken together, these studies have consistently demonstrated positive efficacy and safety of Orviglance, with the Phase 3 SPARKLE study confirming the superior visualization of focal liver lesions in the target population of patients with severe kidney impairment and an adverse event profile consistent with what was observed in the other studies. We are moving ahead with the submission of the marketing approval application, the NDA for Orviglance. We are on track to submit the NDA for Orviglance by mid-2025. Having completed the full study report for SPARKLE, we are now focusing on finalizing our pre-NDA interaction with the FDA by the first quarter of next year. This step is crucial for laying the groundwork for our NDA submission and review, ensuring alignment with the FDA and facilitating a smooth review process. After submission, we expect a standard ten-month review period from the FDA. So in summary, the strong results from the SPARKLE study show that Orviglance provides superior imaging compared to unenhanced MRI, allowing us to move forward into the registration phase of Orviglance. So now I will hand it over to Julie.